SRR1435901
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.489
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.440
- INFLAMMATORY_RESPONSE+0.372
- KRAS_SIGNALING_DN+0.357
- PANCREAS_BETA_CELLS+0.321
- ANGIOGENESIS+0.318
- MYOGENESIS+0.307
- CHOLESTEROL_HOMEOSTASIS+0.297
- COAGULATION+0.297
- APOPTOSIS+0.286
Top 10 suppressed
- MYC_TARGETS_V1-0.542
- OXIDATIVE_PHOSPHORYLATION-0.528
- DNA_REPAIR-0.501
- MYC_TARGETS_V2-0.487
- PROTEIN_SECRETION-0.415
- UNFOLDED_PROTEIN_RESPONSE-0.401
- E2F_TARGETS-0.367
- G2M_CHECKPOINT-0.361
- PI3K_AKT_MTOR_SIGNALING-0.355
- MITOTIC_SPINDLE-0.315
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1440082 | GTEX | — | 0.960 |
| 2 | SRR1341898 | GTEX | — | 0.935 |
| 3 | SRR1797249 | — | cohortMD2 | 0.930 |
| 4 | SRR1444932 | GTEX | — | 0.929 |
| 5 | SRR1383059 | GTEX | — | 0.922 |
| 6 | BS_ZTWGFWTX | pilocytic astrocytoma | — | 0.921 |
| 7 | SRR1329885 | GTEX | — | 0.920 |
| 8 | SRR1316392 | GTEX | — | 0.920 |
| 9 | SRR1352706 | GTEX | — | 0.919 |
| 10 | SRR1071289 | GTEX | — | 0.914 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.489 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.440 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.372 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.357 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.321 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.318 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.307 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.297 | Remibrutinib | — uncovered |
| COAGULATION | 0.297 | Binimetinib | — uncovered |
| APOPTOSIS | 0.286 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.278 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.276 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.272 | Temsirolimus | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.267 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.264 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.263 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.262 | Inavolisib | — uncovered |
| HYPOXIA | 0.247 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.238 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.205 | Idelalisib | — uncovered |